BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 16110748)

  • 1. Prostate cancer: the role of hormonal therapy.
    Salesi N; Carlini P; Ruggeri EM; Ferretti G; Bria E; Cognetti F
    J Exp Clin Cancer Res; 2005 Jun; 24(2):175-80. PubMed ID: 16110748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined androgen blockade: the gold standard for metastatic prostate cancer.
    McLeod DG; Crawford ED; DeAntoni EP
    Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up.
    Akaza H; Homma Y; Usami M; Hirao Y; Tsushima T; Okada K; Yokoyama M; Ohashi Y; Aso Y;
    BJU Int; 2006 Sep; 98(3):573-9. PubMed ID: 16925756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S; Akaza H
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study.
    Ueno S; Namiki M; Fukagai T; Ehara H; Usami M; Akaza H
    Int J Urol; 2006 Dec; 13(12):1494-500. PubMed ID: 17118024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening and hormonal therapy of localized prostate cancer shows major benefits on survival.
    Labrie F
    Cancer J; 2000 Apr; 6 Suppl 2():S182-7. PubMed ID: 10803834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer.
    Abrahamsson PA; Anderson J; Boccon-Gibod L; Schulman C; Studer UE; Wirth M
    Eur Urol; 2005 Dec; 48(6):900-5. PubMed ID: 16257109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary hormonal therapy for advanced prostate cancer.
    Lam JS; Leppert JT; Vemulapalli SN; Shvarts O; Belldegrun AS
    J Urol; 2006 Jan; 175(1):27-34. PubMed ID: 16406864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
    DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
    BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current treatment of advanced prostate cancer.
    Ismail M; Gomella LG
    Tech Urol; 1997; 3(1):16-24. PubMed ID: 9170220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine therapy for prostate cancer.
    Damber JE
    Acta Oncol; 2005; 44(6):605-9. PubMed ID: 16165920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced prostate cancer. Hormonal treatment.
    de la Haba-Rodríguez J
    Tunis Med; 2005 Dec; 83 Suppl 12():71-3. PubMed ID: 16430072
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment options in androgen-independent prostate cancer.
    Lara PN; Meyers FJ
    Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Future prospects for primary hormone therapy in localized and locally advanced prostate cancer].
    Akaza H; Hirao Y; Labrie F; Soloway MS
    Hinyokika Kiyo; 2003 Dec; 49(12):771-7. PubMed ID: 14978964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
    Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormonal therapy for locally advanced prostate cancer.
    Einstein AB
    NCI Monogr; 1988; (7):171-4. PubMed ID: 3050536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.